Insights Archive
Filter by:
April 25, 2025
Plan design development to achieve results.
A well-aligned plan isn’t just cost-effective; it’s built with purpose, supporting your broader healthcare objectives and ensuring long-term impact.
April 25, 2025
6 Ways ClearScript Supports You and Your Members During Open Enrollment—and Beyond
Open enrollment can be a hectic season for HR teams and a confusing time for employees. But it’s also a…
April 25, 2025
Drug Spotlight: Yesintek and Selarsdi
YESINTEK (ustekinumab-kfce)Manufacturer: BioconLaunch Date: 2/24/2025 SELARSDI (ustekinumab-aekn)Manufacturer: Alvotech/TevaLaunch Date: 1/2025 YESINTEK & SELARSDI are biosimilars of reference product STELARA (Ustekinumab),…
March 6, 2025
Don’t let your PBM off the hook!
ClearScript experts Nicole Christian, PharmD, Vice President of Clinical Account Services, and Mackenzie Pfeiffer, Director of Account Management, and Vice President of Sale, Kyle D. Johnson, will share an inside look at the latest PBM challenges, including recent negative press, the rebate debate (including the role of international sourcing), the GLP-1 controversy, and the rise of biosimilars.
February 6, 2025
Drug Spotlight: Suzetrigine
suzetrigine (VX-548) Manufacturer: Vertex Approval Date: 1/30/2025 Suzetrigine possesses a novel mechanism of action as a voltage-gated sodium channel inactivator…
February 6, 2025
20 Years Strong: Celebrating ClearScript’s Legacy of Stewardship to Our Clients
This year marks a significant milestone for ClearScript: 20 years of trusted stewardship in pharmacy benefits. For two decades, we…
February 6, 2025
Better Information at the Point of Care Saves Time and Money for Members, Prescribers, and Clients
In today’s fast-paced healthcare environment, prescribing medications can be challenging for both prescribers and patients. Determining drug coverage, understanding formulary…
November 4, 2024
ClearScript’s Member Portal and Mobile App: Engaging Members, Managing Costs
At ClearScript, we’re committed to simplifying prescription drug benefits with user-friendly digital tools and resources to help members stay informed and engaged with their healthcare.
November 4, 2024
Neffy® (brand name: epinephrine nasal spray)
Neffy® (epinephrine nasal spray) was approved on August 9, 2024, for the emergency treatment of allergic reactions (type I), including those that are life-threatening (anaphylaxis), in adult and pediatric patients weighing at least 66 pounds.